Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgac689 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Jordan J Wright und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Hauptthemen laut MEDLINE: Thyroid Diseases, Neoplasms, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICI) are cancer therapies that are approved for use in at least 19 different cancers. They function by stimulating immune cell responses against cancer, and their toxicities comprise a host of autoinflammatory syndromes that may impact any organ system. Endocrine toxicities occur in as high as 25% to 50% of ICI recipients, depending on the treatment regimen used. These toxicities vary in severity from mild, asymptomatic cases of subclinical hypothyroidism to severe, fatal cases of adrenal crisis, thyroid dysfunction, or diabetic ketoacidosis. Thus, timely recognition and treatment is critical. Herein, we present clinical cases of ICI-induced thyroid dysfunction, hypophysitis, and insulin-dependent diabetes mellitus. We use these cases to discuss the screening, diagnosis, and management of ICI-associated endocrine dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
ORCID-Profile: Jordan J Wright, Douglas B Johnson
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Wright, J. J., & Johnson, D. B. (2023). Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac689
Vancouver
Wright JJ, Johnson DB. Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac689
BibTeX
@article{Wright2023,
author = {Wright, Jordan J and Johnson, Douglas B},
title = {Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgac689}
}
EUVIMED